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Abstract
Introduction High expression of total HER2 protein confers
poor prognosis for breast cancer patients. HER2 is a member of
the HER family consisting of four receptors, HER1 to HER4.
HER receptor activity is regulated by a variety of mechanisms,
and phosphorylation of the C-terminal part of the HER receptors
is a marker for active signaling. The importance of
phosphorylation and thereby activation of the HER1 to HER4
receptors, however, has not been investigated concomitantly in
breast tumors. In the present study we examined the importance
of active HER signaling in breast tumor biopsies and paired
metastases, by evaluating the expression of phosphorylated
HER1, HER2, HER3, Erk, Akt and the total level of HER4 and
HER2.
Methods Immunohistochemical analysis was performed on 268
primary breast tumors and 30 paired metastatic lesions from
postmenopausal women with hormone receptor-positive breast
tumors, who had received adjuvant tamoxifen therapy. The
observed protein expression levels were analyzed for co-
expression, for correlation to clinicopathological parameters and
for prognostic value in relation to disease-free survival and
overall survival. Lastly, the difference between protein levels in
primary tumors versus metastasis was evaluated.
Results In the primary tumors, 8%, 18%, 14% and 15% of
cases were scored positive for total HER2, pHER1, pHER2 and
pHER3 expression, respectively. HER4 was expressed with
strong intensity in 68% and at moderate intensity in 29% of
cases. The activated forms of Akt and Erk were quite uniformly
expressed in the categories; negative, moderate or strong. In
univariate analysis, expression of total HER2, pHER1, pHER2
and pHER3 was significantly associated with poor disease-free
survival. Strong HER4 expression was associated with
prolonged disease-free as well as with overall survival.
Expression of pAkt and pErk was not correlated with survival. In
multivariate analysis, pHER2 expression was clearly an
independent marker for poor disease-free survival and overall
survival when tested against tumor size, tumor grade, nodal
status and HER2. Lastly, comparison of HER receptor
expression in metastatic versus primary tumors showed a
significant increase in expression of pHER1 and pHER3 in the
metastases.
Conclusions In hormone receptor-positive breast cancer,
determination of pHER2 yields additional prognostic information
about poor prognosis compared with the current clinical
standard for measuring HER2.
Introduction
The epidermal growth factor receptor family constitutes four
members: HER1 (EGFR/ErbB1), HER2 (ErbB2), HER3
(ErbB3) and HER4 (ErbB4). The four receptors are activated
by binding of numerous ligands, which leads to heterodimeri-
zation or homodimerization and subsequent phosphorylation
of specific tyrosine residues in the intracellular region. This
activation by phosphorylation results in regulation of a variety
of cellular processes including cell proliferation and survival.
Much evidence suggests that the kinases Akt and Erk mediate
a substantial part of the HER signaling [1].
FISH: fluorescence in situ hybridization; IHC: immunohistochemical; p: phosphorylated.Breast Cancer Research    Vol 11 No 1    Frogne et al.
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In breast cancer, excellent work has been done to investigate
the significance of HER signaling for prognosis, both by char-
acterization of the HER dimers [2] as well as of the ligands [3].
The most studied receptors in breast cancer are HER1 and
HER2; overexpression of HER2 generally occurs in about
20% of breast carcinomas, and is more frequent in estrogen
receptor-negative than in estrogen receptor-positive cases
[4]. HER1 and HER2 overexpression is generally associated
with more aggressive tumors and poor prognosis [2,5-7]. The
importance of HER3 has been less investigated, but from in
vitro studies it is becoming clear that HER3 is involved in
tumor growth and also in resistance to both endocrine and
HER-directed treatment [8-10]. Several recent clinical studies
have found HER3 to correlate with adverse clinicopathological
properties [2,11,12]. Association with better prognosis, how-
ever, has also been reported [13,14]. The role of HER4 in
breast cancer has also been investigated – and in estrogen
receptor-positive breast cancer cell lines, HER4 is often found
to mediate growth inhibition and cell differentiation [15,16].
Analysis of tumor biopsies generally shows that expression of
HER4 is associated with prolonged survival [2,6,14,17,18].
In the clinical setting today, only three protein biomarkers are
used; estrogen receptor, progesterone receptor and HER2.
The golden standard for determination of HER2 positivity is
evaluation by immunohistochemistry (IHC); and for IHC equiv-
ocal cases, this is followed by fluorescence in situ hybridiza-
tion (FISH) analysis for determination of gene amplification.
Patients with HER2-positive tumors are candidates for treat-
ment with the monoclonal anti-HER2 antibody trastuzumab.
Numerous other approaches, however, are currently being
evaluated in clinical trials for their ability to inhibit HER1 and/
or HER2 or all four HER receptors [19]. It is therefore impor-
tant to have good quality biomarkers to ensure that the patient
is offered optimal treatment.
Our intention with the present study was to concomitantly
evaluate the activation status of HER1, HER2 and HER3 and
to determine their importance in hormone receptor-positive
breast cancer. We hereby aimed to find new and superior
biomarkers for detection of poor prognosis, and also to sug-
gest new markers for future investigations regarding predic-
tion of benefit from endocrine and/or anti-HER therapy. We
therefore measured the levels of HER1, HER2 and HER3,
which were phosphorylated at tyrosine sites described to be
important for activation of the receptors [20], as well as the
levels of the activated form of the downstream target kinases
Erk and Akt. We were also interested in determining the
amount of pHER4, but we were not able to find a commercially
available anti-pHER4 antibody that was pHER4 specific and
applicable in IHC analysis. Instead, we measured total HER4
expression using an antibody against the C-terminal region.
Overall, we report the analysis of phosphorylated HER1,
HER2, HER3, Erk, and Akt as well as total HER2 and HER4
expression levels in 268 hormone receptor-positive primary
tumors and 30 corresponding metastases from postmenopau-
sal women treated adjuvantly with tamoxifen.
Materials and methods
Patients
A total of 268 postmenopausal patients were used for this
study, all of which underwent surgery for primary invasive
breast cancer between 1989 and 2001 at Odense University
Hospital. Patients were classified as high risk, according to
age (<75 years) and/or tumor size (> 2 cm) and/or Bloom and
Richardson grade ( 2) and/or positive nodal status. The high-
risk patients received tamoxifen as the first-line adjuvant treat-
ment and all, except a single case, were positive for either
estrogen receptor and/or progesterone receptor. Owing to
side effects, 25 patients were subsequently crossed over from
tamoxifen to megace or letrozole. The only other criterion for
entering this study was that both paraffin-embedded and fro-
zen tumor tissue was present.
The standard clinicopathological parameters are presented in
Table 1. HER2 positivity was determined according to current
standardized guidelines for HER2 testing; that is, IHC fol-
lowed by FISH analysis for cases scoring 2+. The analysis was
performed with the HercepTest™ for IHC and with pharmDx™
for FISH (both from DAKO A/S, Glostrup, Denmark).
The total number of malignancy graded tumors was only 228;
this was due to tumors of lobular subtype and tumors of rare
subtypes, which were not graded. Table 2 presents the patient
characteristics and treatment characteristics. It should also be
mentioned that only a single patient experienced relapse while
receiving tamoxifen.
The analyses on the clinical material have been approved by
the local ethics committee for Region South Denmark, S-VF-
20040064.
Tumor material and construction of tissue microarrays
Archival formalin-fixed and paraffin-embedded primary tumor
tissue was used to generate tissue microarrays comprised of
two 2 mm cores from each tumor, as previously described
[21]. For positive controls, we included tissue cores of epider-
mis (pHER1), striated muscle (HER4) and of the MCF-7 cell
line, which had been treated with the HER3/4 family ligand
heregulin 1 (recombinant heregulin 1, 396-HB/CF; R&D
Systems Europe Ltd, Abingdon, UK; pHER2, pHER3, HER4).
Cores on each tissue miroarray were therefore known to
express a high amount of the six proteins evaluated in this
study. Negative controls were obtained by omitting the primary
antibody.
Tumor metastases were available from 30 patients and were
mostly distant metastases; for example, from skin (six
patients), bone (four patients), bone marrow (three patients),
pleural effusions (three patients), soft tissue (four patients),Available online http://breast-cancer-research.com/content/11/1/R11
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Table 1
Clinicopathological parameters
Parameter n %
World Health Organization diagnosis
Invasive ductal 230 86
Invasive lobular 32 12
Ductal with ductal carcinoma in situ 21
Unknown 41
Total 268
Tumor grade
1 62 27
2 103 45
3 63 28
Total 228
Tumor size
<2 cm 85 32
2 to 5 cm 161 60
>5 cm 22 8
Total 268
Nodal status
0 22 8
1 to 3 149 56
4 97 36
Total 268
Receptor status (estrogen receptor or progesterone receptor)
Negative 10
Positive 267 100
Total 268
HER2
Negative 246 92
Positive 22 8
Total 268
Recurrence
No 179 67
Yes 89 33
Total 268
Death
No 146 54
Yes 122 46
Total 268
Tumor grade was scored according to Bloom and Richardson. HER2 was analyzed by standard testing (that is, the HercepTest™), followed by 
fluorescence in situ hybridization analysis of the cases scoring 2+.Breast Cancer Research    Vol 11 No 1    Frogne et al.
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peripheral lymph nodes (two patients) and visceral organs
(eight patients).
Immunohistochemistry
Serial sections of 5 m thickness were cut from the tissue
microarrays, dewaxed and rehydrated. To block endogenous
peroxidase, the slides were incubated in 1.5% hydrogen per-
oxide in Tris-buffered saline for 10 minutes.
Antigen retrieval was performed by three methods. When
staining for pHER1, pHER2, pAkt or pErk, heat-induced
epitope retrieval was performed by microwave oven for 15
minutes in TEG buffer (10 mM Tris, 0.5 mM ethylene glycol
tetraacetic acid, pH 9); for pHER3, the TEG buffer was
replaced with 1 mM ethylenediamine tetraacetic acid at pH 8.
Antigen retrieval for the HER4 staining was done by a 15-
minute protease treatment.
Incubation with primary antibody for 60 minutes at room tem-
perature was followed by detection of the primary antibody
using the Advance™ HRP system (DAKO). The applied chro-
mogen was 3,3'-diaminobenzidine and all stainings were per-
formed in the Autostainer Plus Link Instrument (DAKO). After
washing, the slides were counterstained with Meyer's hema-
toxylin for 30 seconds. The following antibodies were used:
pHER11173  (dilution factor 1:200, catalog number 4407),
pHER21221/1222 (dilution factor 1:200, catalog number 2243),
pHER31289  (dilution factor 1:100, catalog number 4791),
HER4c-terminal  (dilution factor 1:250, catalog number RB-
9045), pErk202/204 (dilution factor 1:1000, catalog number
4376) and pAkt473 (dilution factor 1:200, catalog number
3787). The HER4 antibody was from Thermo Fisher Scientific
(Fremont, CA, USA), whereas all other antibodies were from
Cell Signaling Technology (Danvers, MA, USA), which in the
datasheets for the antibodies against the individual HER
receptor demonstrated no cross-reaction to the other HER
receptors.
Evaluation of immunohistochemistry data
Two different scoring methods were used in the present study.
The markers with predominantly membrane staining (HER2,
pHER1, pHER2 and pHER3) were scored according to the
HercepTest™ guidelines. For markers with predominantly cyto-
plasmic staining (HER4, pAkt and pErk), the overall staining
intensity was scored.
In the HercepTest™: 0 = no staining or membranous staining
in <10% of invasive tumor cells; 1 = faint or barely perceptible
membranous staining in >10% of invasive tumor cells; and 2
= moderate and 3 = strong complete membranous staining in
>10% of invasive tumor cells, respectively.
The overall staining intensity (that is, staining of membrane,
cytoplasm and/or nucleus) was scored if >10% of the tumor
cells were positive. We used a scale from 0 to 2: 0 = negative,
1 = moderate and 2 = strong staining intensity.
Furthermore, nuclear reactivity of all stainings was scored as
either negative or positive, again with a cutoff value of 10%
positive tumor cells.
TF scored all primary tumors and A-VL scored all metastases
as well as 25% of the primary tumors. The scores from the two
observers were not different by McNemar's test, and the
kappa statistic ranged from 0.8 to 1.0. The six investigated
proteins were scored in two cores from each tumor in approx-
imately 90% of cases, whereas the remaining cases were
scored from a single core. In the rare cases where the two
score values differed by 2, the highest score value was used
[21].
Statistical analysis
Spearman correlation coefficients and Fisher's exact test were
used to determine significant associations between the
expression levels of the investigated proteins as well as to the
clinicopathological parameters. Survival curves were gener-
ated by Kaplan–Meier estimates followed by the log-rank test.
The Cox proportional hazards model was used to evaluate the
prognostic value of the markers both alone (univariate) and in
combination (multivariate) with the current standard markers:
tumor grade, tumor size, nodal status and HER2. Lastly, the
Sign test was used to evaluate differences between the pro-
tein expression levels of primary and metastatic tumors. All
tests were two sided and P < 0.05 was considered significant.
SAS 9.1 software (SAS Institute Inc., Cary, NC, USA) was
used for all analyses.
Results
Expression levels of phosphorylated HER1, HER2, HER3, 
Erk and Akt and total HER4
Membrane reactivity of pHER1, pHER2 and pHER3 was eval-
uated using the HercepTest™ score method, as described in
Materials and methods. Expression of pHER1 was evaluated
in 264 cases and 18% had a detectable membrane staining,
of which the majority were weak (score 1) and a few showed
moderate intensity (score 2). No tumors with strong (score 3)
pHER1 membrane staining were observed. Expression of
Table 2
Patient and treatment characteristics
Median (years) Range (years)
Age 61 48 to 74
Time on tamoxifen 1.8 0.4 to 6.0
Time to recurrence 3.1 0.12 to 16.2
Time to death 5.9 0.26 to 15.7
Time of follow up 12.4 6.3 to 19.2Available online http://breast-cancer-research.com/content/11/1/R11
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pHER2 was analyzed in 264 tumors and membrane staining
with scores 1, 2 and 3 was recorded in 27%, 11% and 4% of
cases, respectively. The moderate and strong pHER2 mem-
brane reactivity was very often accompanied by cytoplasmic
staining. We evaluated pHER3 expression in 261 cases and
the strongest expression was found in the membrane and
nucleus, but staining was also observed in the cytoplasm.
Weak membrane staining was observed in 11% of cases, and
only 3% and 1% were recorded with the scores 2 and 3,
respectively. Interestingly, we also observed substantial
nuclear pHER3 staining in 10% of the 261 cases. Expression
of HER4 was evaluated in 259 cases and the staining was pre-
dominantly cytoplasmic, but most often in conjunction with a
variable amount of membrane reactivity. We did not observe
nuclear reactivity with this HER4 antibody. Owing to the con-
siderable amount of cytoplasmic reaction, the HER4 staining
was not scored by the HercepTest™ but by the overall inten-
sity, grouped as either negative (score 0), moderate (score 1)
or strong (score 2). The moderate intensity was observed in
29% of cases, 68% showed the strong intensity and only 3%
were negative. Figure 1 shows representative pictures of the
observed staining patterns of the four HER receptors.
The same overall intensity score was used to record the
expression level of pErk (256 cases) and of pAkt (261 cases).
Both the pErk and pAkt stainings were cytoplasmic and
nuclear. The pErk expression was quite heterogeneous espe-
cially in the nucleus, whereas pAkt was more homogeneous
and the same intensity was usually observed in both the cyto-
plasm and nucleus. We observed a fairly even distribution of
cases in the three categories, with a few more pErk-negative
tumors and slightly more tumors expressing a moderate level
of pAkt. Based on these initial frequency data, we decided to
assess pHER1 and pHER3 as either negative (score 0) or
positive (scores 1, 2 and 3), to assess pHER2 as either nega-
tive (score 0), weak (score 1) or strong (scores 2 and 3), and
to assess HER4 as either low (scores 0 and 1) or high (score
2). The pErk and pAkt scores were analyzed in the original cat-
egories.
Figure 1
Immunohistochemical staining of primary breast tumors Immunohistochemical staining of primary breast tumors. (a) Moderate-intensity membranous pHER1. (b) Strong-intensity membranous pHER2. (c) 
Moderate-intensity membranous pHER3. (d) Nuclear pHER3. (e) Moderate HER4 intensity. (f) Strong HER4 intensity.Breast Cancer Research    Vol 11 No 1    Frogne et al.
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Correlations between protein expression levels
Table 3 presents the protein expression levels and their fre-
quencies in relation to each other. Fisher's exact test was used
to determine significant correlations between the investigated
protein expression levels. We found strong positive correlation
between membrane expression of HER2, pHER2 and pHER3.
Briefly, 68% of the HER2-positive cases also showed strong
pHER2 expression, while 28% of HER2-positive cases dis-
played weak pHER2 expression. Only a single patient there-
fore had a HER2-positive tumor without concurrent expression
of pHER2. Conversely, only 39% of the strong-expressing
pHER2 cases were found to be HER2-positive. Of the remain-
ing HER2-negative and pHER2-positive cases (23 cases,
61%), 15 were scored 0 with the HercepTest™, six were
scored +1, and two were scored +2 and without amplification.
The HER2-negative cases with strong pHER2 expression
were in 82% of cases expressed concomitant with pHER1
and/or pHER3. pHER2-positive cases that were scored
HER2-positive expressed pHER1 and/or pHER3 in 74% of
cases. The activated HER2 is therefore generally co-
expressed with at least one other activated HER receptor that
has the capacity to function as a dimerization partner. We
used serial sections, and Figure 2 is a representative picture
showing co-expression of all three phosphorylated receptors
in the same tumor cells. Lastly, pHER2, but not HER2, was
negatively correlated to HER4 expression.
Expression of the activated form of the intracellular kinases Akt
and Erk was highly correlated, and pAkt was also associated
with expression of pHER2 and pHER3 – and perhaps also
with pHER1 (P = 0.057). No significant correlations between
pErk and the HER receptors were observed.
Associations between protein expression levels and 
standard clinicopathological parameters
Table 4 presents the classification of the observed protein
expression levels in relation to the parameters of tumor grade,
tumor size, nodal status, recurrence and death. From these
distributions we used Fisher's exact test to analyze for poten-
tial significant correlations. Expression of HER2, pHER1 and
pHER2 was found to correlate with recurrence. For HER2 and
pHER2 we also found a positive correlation with high tumor
grade, but interestingly only pHER2 was associated with the
event of death. In contrast, we observed negative correlations
between HER4 expression and grade, recurrence and death.
Lastly, pAkt and pErk were not associated with the standard
clinicopathological parameters.
Kaplan–Meier plots for the HER receptors in relation to 
disease-free survival
Figure 3 shows the Kaplan–Meier plots of pHER1, pHER2,
pHER3 and HER4 expression levels in relation to disease-free
survival. All four markers were found to be significantly associ-
ated with disease-free survival. Most of all, strong but not weak
expression of pHER2 was highly associated with decreased
disease-free survival. Likewise, although not as significant,
expression of pHER1 and pHER3 was also found to correlate
with reduced disease-free survival. In contrast, a high amount
of HER4 was clearly associated with prolonged disease-free
survival.
Cox univariate and multivariate regression analysis of 
variables in relation to disease-free survival and overall 
survival
Based on the Kaplan–Meier plots we performed a Cox regres-
sion with the variables analyzed in the following categories:
tumor grade (1 and 2 vs. 3), tumor size (<25 mm vs.  25 mm),
Figure 2
Immunohistochemical staining of primary breast tumor positive for activated forms of HER1, HER2 and HER3 Immunohistochemical staining of primary breast tumor positive for activated forms of HER1, HER2 and HER3. Immunohistochemical staining of 
serial sections of a primary breast tumor showing that the same cells are positive for the activated forms of HER1, HER2 and HER3. (a) Membra-
nous pHER1. (b) Membranous pHER2. (c) Membranous pHER3.Available online http://breast-cancer-research.com/content/11/1/R11
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nodal status (0 vs.  1), HER2 (negative vs. positive), pHER1
(negative vs. positive), pHER2 (negative and weak vs. strong),
pHER3 (negative vs. positive), and HER4 (low vs. high). The
results from the univariate Cox analysis are presented in Table
5; as expected, we found that high tumor grade, large tumor
size and positive nodal status were significantly associated
with poorer disease-free survival and overall survival. Also as
anticipated, HER2 positivity was associated with poor dis-
ease-free survival; however, this positivity did not reach statis-
tical significance in relation to overall survival (P = 0.06). For
the other HER receptors, the Cox analysis confirmed the Kap-
lan–Meier plots with respect to disease-free survival, but inter-
estingly we also found that strong pHER2 was highly
associated with a reduction in overall survival. Likewise, a high
amount of HER4 correlated with an increased period of overall
survival. Lastly, we did not find expression of pErk or pAkt to
be associated with survival in this patient series (data not
shown).
Table 3
Correlations between protein expression levels
HER2 pHER1 pHER2 pHER3 HER4 pErk
(-) (+) (-) (+) (-) Weak Strong (-) (+) Low High (-) Moderate Strong
pHER1
Negative 202 15
Positive 40 7
P value 0.083
pHER2
Negative 154 1 148 7
Weak 65 6 55 15
Strong 23 15 13 25
P value <0.0001 (+) <0.0001 (+)
pHER3
Negative 211 10 199 21 144 61 14
Positive 28 12 13 26 6 10 24
P value <0.0001 (+) <0.0001 (+) <0.0001 (+)
HER4
L o w 7 5 1 06 9 1 64 9 1 6 1 9 7 1 1 3
High 163 12 142 31 102 53 19 145 27
P value 0.234 0.865 0.021 (-) 1.000
pErk
Negative 103 10 97 16 70 25 17 99 12 44 65
Moderate 56 5 47 14 31 21 9 52 9 17 42
Strong 75 7 65 15 46 24 11 64 17 22 60
P value 1.000 0.328 0.495 0.146 0.073
pAkt
Negative 66 4 63 7 55 9 6 64 4 28 39 48 15 7
Moderate 99 7 88 17 58 30 17 87 17 34 71 40 22 37
Strong 74 11 64 21 40 30 15 66 18 21 62 23 22 37
P value 0.213 0.057 0.002 (+) 0.021(+) 0.102 <0.0001 (+)
Fisher's exact test was used to obtain the P values. (+) and (-), positive and negative correlations. Bold data represent significant values.Breast Cancer Research    Vol 11 No 1    Frogne et al.
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For the multivariate Cox regression we initially included all var-
iables in a single model, which showed that only positive nodal
status and high HER4 expression were significant predictors
of decreased and prolonged survival, respectively (data not
shown). This result is in agreement with the strong correlations
between HER2, pHER1, pHER2 and pHER3, and therefore
this analysis does not give a truthful picture of the importance
of the three phosphorylated HER receptors. We therefore
tested pHER1, pHER2 or pHER3 alone in a model containing
the current standard of clinical biomarker parameters (that is,
Table 4
Protein expression levels in relation to clinicopathological properties
Tumor grade Tumor size Nodal status Recurrence Death
123< 2  c m2  t o  5  c m > 5  c m01  t o  34N o Y e s N o Y e s
HER2
Negative 61 96 49 78 149 19 22 137 87 169 77 137 109
Positive 1 7 14 7 12 3 0 12 10 10 12 9 13
P value 0.0003 (+) 0.506 0.335 0.034 (+) 0.190
pHER1
Negative 50 82 49 62 136 19 16 125 76 150 67 121 196
Positive 10 20 14 20 24 3 6 21 20 25 22 22 25
P value 0.731 0.188 0.180 0.042 (+) 0.333
pHER2
Negative 43 57 24 49 92 14 12 88 55 105 50 91 64
Weak 17 26 22 20 47 4 8 42 21 55 16 41 30
S t r o n g 11 9 1 7 1 2 2 2 4 21 6 2 0 1 6 2 2 1 2 2 6
P value 0.0001 (+) 0.811 0.189 0.001 (+) 0.009 (+)
pHER3
Negative 50 88 50 69 134 18 20 123 78 153 68 122 99
Positive 10 15 13 12 25 3 2 21 17 22 18 20 20
P value 0.582 1.000 0.607 0.099 0.606
HER4
Low 10 32 27 24 49 12 7 41 37 38 47 36 49
High 51 67 35 56 109 10 13 105 57 133 42 104 71
P value 0.004 (-) 0.088 0.174 <0.0001 (-) 0.012 (-)
pErk
Negative 20 45 35 32 72 9 12 57 44 76 37 63 50
Moderate 13 25 11 18 40 3 4 33 24 42 19 32 29
Strong 22 32 16 27 45 10 5 50 27 52 30 42 40
P value 0.261 0.514 0.593 0.798 0.817
pAkt
Negative 10 29 20 20 46 4 8 33 29 48 22 42 28
Moderate 30 34 26 38 59 9 9 54 43 64 42 58 48
Strong 20 39 16 23 54 8 5 55 25 60 25 42 43
P value 0.103 0.588 0.195 0.287 0.419
Fisher's exact test was used to obtain the P values. (+) and (-), positive and negative correlations. Bold data represent significant values.Available online http://breast-cancer-research.com/content/11/1/R11
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tumor grade, tumor size, nodal status and HER2). The results
in Table 6 show that strong pHER2 expression was a signifi-
cant and independent predictor of decreased disease-free
survival. Furthermore, strong pHER2 expression highly signifi-
cantly predicted for reduced overall survival, in contrast to the
current HER2 analysis.
In this multivariate model, expression of pHER1 and pHER3
did not have independent prognostic value (data not shown).
Comparison of frequencies of protein expression levels 
between 30 primary tumors and their corresponding 
metastases
In addition to the primary tumor material, we also analyzed the
protein expression levels of the six markers in 30 distant
metastases from 30 patients within the original group. Table 7
presents the expression frequencies in the primary tumor and
in the metastatic tumors. The final column in Table 7 presents
the P values from a Sign test showing that membrane expres-
sion of pHER1 and pHER3 as well as nuclear expression of
pHER3 were significantly increased in the metastases. No dif-
ference in expression was observed with respect to pHER2.
The pHER2 level in the 30 primary tumors was already mark-
edly increased, however, compared with the average pHER2
expression level of the original 264 primary tumors. Lastly, the
HER4 expression appeared to decrease, but this change was
not statistically significant.
Discussion
The present study investigated the prognostic value of the
activated HER1, HER2 and HER3 receptors, the total HER4
expression and the activated form of the downstream kinases
Akt and Erk. We addressed this issue in a series of postmen-
opausal patients presenting with primary hormone receptor-
positive breast cancer, who had all received adjuvant
tamoxifen therapy.
Figure 3
Kaplan–Meier curves showing disease-free survival in relation to protein expression levels Kaplan–Meier curves showing disease-free survival in relation to protein expression levels. (a) pHER1: negative (0), positive (1). (b) pHER2: nega-
tive (0), weak (1), strong (2). (c) pHER3: negative (0), positive (1). (d) HER4: moderate (1), strong (2).Breast Cancer Research    Vol 11 No 1    Frogne et al.
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Total HER2 expression is an independent predictor of poor
prognosis [2,7] and is also a clinical target for treatment [22].
In this study, 8% of the patients had HER2-positive tumors in
accordance with this being a hormone receptor-positive pop-
ulation, and HER2 positivity was associated with shorter dis-
ease-free survival. Fourteen percent of cases were recorded
with strong membrane expression of HER2 phosphorylated at
tyrosine 1221/1222, however, and this HER2 phosphorylation
was associated with high tumor grade and with shorter dis-
ease-free survival and overall survival. We speculate that the
reason for this difference is due to the fact that moderate or
even low levels of HER2 may be sufficient to elicit a potent
mitogenic signal, upon activation by dimerization with ligand
activated HER1 or HER3. This hypothesis is not new [23], and
especially the importance of the HER ligands for activation of
the HER receptors has been substantiated by several reports
[3,24-26]. In agreement, we find that the hormone receptor-
positive breast cancer cell line MCF-7, which we score HER2-
negative, has weak to moderate levels of HER2 mRNA and
protein [27], and addition of the HER3/HER4 ligand heregulin
1 clearly abrogated the inhibitory effect of antiestrogen treat-
ment equally well in both wild-type and HER2/HER3 overex-
pressing MCF-7 cells – suggesting that activation of even a
low level of HER2 via dimerization of ligand-activated HER3
may suffice to protect against antiestrogen therapy [27].
A recent study has compared HER2 mRNA expression in
MCF-7 cells with mRNA expression in tumors classified as
HER2-negative or HER2-positive, and the HER2 mRNA level
in MCF-7 cells was lower than in most HER2-negative tumors
[28]. This supports tumors classified as HER2-negative per-
haps having sufficient HER2 protein to elicit signal transduc-
tion upon activation, and thereby may explain why also some
patients with HER2-negative tumors respond to trastuzumab
treatment [28].
It is noteworthy that 82% of cases with strong pHER2 staining
without HER2 overexpression were scored positive for
Table 5
Cox univariate regression analyses of variables in relation to disease-free survival and overall survival
Variable Disease-free survival Overall survival
P value Relative risk (95% CI) P value Relative risk (95% CI)
Tumor grade 0.0201 1.767 (1.093 to 2.86) 0.0072 1.785 (1.170 to 2.725)
Tumor size 0.0007 2.070 (1.357 to 3.160) 0.0052 1.662 (1.164 to 2.375)
Nodal status <0.0001 3.193 (2.091 to 4.876) <0.0001 2.205 (1.545 to 3.148)
HER2 0.0037 2.470 (1.342 to 4.546) 0.0595 1.739 (0.978 to 3.093)
pHER1 0.0346 1.683 (1.038 to 2.726) 0.2317 1.309 (0.842 to 2.033)
pHER2 <0.0001 2.699 (1.662 to 4.384) 0.0002 2.273 (1.470 to 3.513)
pHER3 0.0489 1.686 (1.002 to 2.835) 0.3926 1.233 (0.763 to 1.995)
HER4 <0.0001 0.361 (0.238 to 0.549) 0.0111 0.624 (0.433 to 0.898)
Variables were analyzed as follows: tumor grade (1 and 2 vs. 3), tumor size (<25 mm vs.  25 mm), nodal status (0 vs.  1), HER2 (negative vs. 
positive), pHER1 (negative vs. positive), pHER2 (negative and weak vs. strong), pHER3 (negative vs. positive), HER4 (low vs. high). 95% CI, 95% 
confidence interval. Bold data represent significant values.
Table 6
Cox multivariate regression analyses of selected variables in relation to disease-free survival and overall survival
Variable Disease-free survival Overall survival
P value Relative risk (95% CI) P value Relative risk (95% CI)
Tumor grade 0.544 1.17 (0.71 to 1.92) 0.187 1.35 (0.87 to 2.09)
Tumor size 0.018 1.76 (1.10 to 2.80) 0.060 1.48 (0.98 to 2.21)
Nodal status <0.0001 3.11 (1.90 to 5.11) 0.0001 2.29 (1.50 to 3.49)
HER2 0.097 1.84 (0.90 to 3.78) 0.574 1.22 (0.62 to 2.40)
pHER2 0.009 2.14 (1.21 to 3.78) 0.005 2.10 (1.25 to 3.52)
Variables were included in the following categories: tumor grade (1 and 2 vs. 3), tumor size (<25 mm vs.  25 mm), nodal status (0 vs.  1), HER2 
(negative vs. positive), pHER2 (negative and weak vs. strong). 95% CI, 95% confidence interval. Bold data represent significant values.Available online http://breast-cancer-research.com/content/11/1/R11
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pHER1 and/or pHER3, clearly supporting that HER2 may be
activated via dimerization with another HER family member.
This is further supported by the finding that pHER2 was often
expressed in the same tumor cells that were also positive for
pHER1 and/or pHER3 (Figure 2). Our multivariate analysis
clearly revealed that IHC evaluation of tyrosine 1221/1222
pHER2 was significantly better than the current HER2 tests
with respect to select patients with both poor disease-free sur-
vival and overall survival. Other studies have also indicated that
pHER2 expression may provide additional survival information
[23,29,30]. In two of these studies, IHC detection of pTyr
1248 was measured and only a small fraction of the HER2-
positive cases (12%) was positive for pHER2 [23,29]. In the
study by Cicenas and colleagues [30], the same antibody
against pTyr1248 was applied in a highly sensitive chemolumi-
nescence-linked immune assay. In that study, pHER2 expres-
sion was found in both HER2-positive and HER2-negative
tumors (68% and 27%, respectively). In concert with our find-
ing, the multivariate analysis showed that pHER2 was a marker
of poor prognosis independent of HER2. We have tested the
antibody against pTyr 1248, but found only weak staining in
our positive controls, indicating that this antibody may not be
sensitive enough for IHC analysis as also suggested by Cice-
nas and colleagues [30]. We therefore selected the antibody
against pTyr 1221/1222 directed against phosphotyrosines,
which like pTyr 1248 is related to HER2 receptor activation
[20]. Our data support that the pTyr1221/1222 antibody is a
good antibody for IHC detection of activated HER2.
Future studies shall validate the clinical usefulness of the pTyr
1221/1222 antibody with respect to predict response to
endocrine therapy and also in relation to predict response to
therapy directed against the activated HER2 receptor. Our
finding that activated HER2 is expressed also in HER2-nega-
tive tumors indicates that these tumors may utilize HER2
receptor signaling to promote growth, and thus may be poten-
tial responders to treatment targeting the activated HER2.
Besides trastuzumab, which has been found to be beneficial
also in a fraction of the patients with HER2-negative tumors
[28], targeted therapy may involve the monoclonal antibody
Pertuzumab, which targets HER2 receptor dimerization [31],
or treatment with the tyrosine kinase inhibitor Lapatinib, which
targets the kinase activity of both HER2 and HER1 [32].
In the present series, membrane expression of phosphorylated
HER3 at tyrosine 1289 was found in 15% of cases and was
associated with shorter disease-free survival. No previous
work has investigated the importance of phosphorylated
HER3 in primary breast cancers, but most studies of total
HER3 expression have found HER3 to correlate with adverse
clinicopathological properties [2,5,6,11,33,34]. Contrary
results have also been observed, however; for example,
inverse association with local recurrence [2] and association
with longer survival [13,14]. In breast cancer cell lines, HER3
is a promoter of cell growth and is required for HER2-medi-
ated proliferation [35]. More recently, HER3 activation has
also been shown to be important for both tamoxifen-resistant
and fulvestrant-resistant cell growth [10,36], and a significant
role for HER3 in resistance towards HER-directed therapy is
also evident [37,38]. In the present patient series, membrane
expression of pHER3 did not add prognostic information to
the current clinical parameters, hence substantiating that
Table 7
Frequencies of protein expression levels between primary and metastatic tumors
Protein Primary tumors Metastatic tumors Sign test, P value
0120 1 2
pHER1 25 -- 5 11 -- 19 0.0003
pHER2 17 5 7 14 10 6 0.6072
pHER3 23 -- 5 16 -- 13 0.0034
Nuclear pHER3 27 -- 1 15 -- 14 0.0002
HER4 -- 13 17 -- 19 10 0.1435
Cytoplasmic pErk 10 4 15 6 12 12 1.0000
Nuclear pErk 10 3 16 6 6 18 0.4545
Cytoplasmic pAkt 3 19 8 10 5 14 0.8036
Nuclear pAkt 16 8 8 10 7 12 0.0768
Category 0 = number of negative cases, category 1 = number of weak-expressing (pHER2), low-expressing (HER4) or moderate-expressing 
(pErk and pAkt) cases, and category 2 = number of positive (pHER1 and pHER3) or strong-expressing (pHER2, pErk and pAkt) cases. 
Expression of pHER1, pHER3 and nuclear pHER3 was analyzed as negative or positive, hence '--' in category 1. HER4 expression was evaluated 
as either low or high, hence '--' in category 0. The Sign test was used to examine for significant differences in protein expression levels between 
primary and metastatic tumors. Bold data represent significant values.Breast Cancer Research    Vol 11 No 1    Frogne et al.
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HER2 is the dominant HER receptor and that the function of
HER3 is primarily to act as a co-activator of HER2. Moreover,
nuclear expression of pHER3 was found in 10% of the patient
tumors, but it was not significantly associated with the param-
eters investigated in the present series.
We observed membrane expression of HER1 phosphorylated
at tyrosine 1173 in 18% of cases, and to the best of our knowl-
edge only two other studies have measured pHER1 in breast
cancer biopsies. These investigations were carried out on 225
and 154 cases of advanced breast cancer, and 7% and 36%
of cases displayed membrane staining, respectively [39,40]. In
agreement with these studies, our work showed that pHER1
was significantly correlated to shorter disease-free survival.
Moreover, high total HER1 expression is also generally related
to poor prognosis [2,5,6]. Overall, however, the literature on
the prognostic value of total HER1 expression in breast cancer
is not completely clear [41]. Our analyses show that mem-
brane expression of pHER1 did not add prognostic value to
the current clinical parameters, thus indicating that HER1, like
HER3, also mainly acts as a co-activator of HER2.
In contrast to the predominantly membrane staining of total
HER2, pHER1, pHER2 and pHER3, the HER4 staining was
primarily cytoplasmic but also membranous. The overall inten-
sity scoring method was therefore applied. HER4 expression
was found in 97% of cases. The high percentage of positive
cases is in concert with the data from Abd El-Rehim and cow-
orkers, who found 80% HER4-positive cases in a series of
more than 1,500 patients [2], and another study recorded
82% HER4-positive cases [18]. When only reactivity in the
membrane is scored, however, the observed frequencies are
much lower: 21% [17], 14% [5], and 12% [6]. In agreement,
we found 15% of cases to express HER4 in the membrane. In
this series, high HER4 expression was inversely associated
with pHER2 and tumor grade, and had a positive effect on dis-
ease-free survival and overall survival. Furthermore, high HER4
expression independently predicted for longer disease-free
survival and overall survival, compared with the currently used
parameters. This result is much in line with earlier data from
both protein and mRNA analyses, where HER4 predicted pro-
longed survival in multivariate analysis [6,14]. Moreover, oth-
ers have found associations between high HER4 expression
and longer disease-free survival and/or overall survival com-
pared with low or negative cases [17,18].
We also looked at the activated levels of the HER downstream
kinases Erk and Akt – we found that pAkt was correlated with
pHER2, pHER3 and pErk, whereas pErk was not correlated
with any of the HER receptors. Our data therefore suggest
that pAkt is likely to be an important downstream mediator of
HER2/HER3 signaling, which is very much in line with the cur-
rent knowledge [8]. We did not find associations, however,
between pAkt or pErk and clinicopathological parameters or
survival. For pAkt this is in agreement with a study of 691
cases where the authors did not find an association with sur-
vival [42]. In contrast, others have observed pAkt expression in
54% of 93 patients analyzed and have shown that pAkt was
an independent marker for disease-free survival [43]. Also,
another study of 399 cases found pAkt to be associated with
decreased overall survival in univariate analysis [44]. Few stud-
ies have been conducted for pErk, and also here conflicting
results have been obtained. Using both immunoblotting and
IHC, it has been shown by multivariate analysis that pErk was
a marker for prolonged survival [45], while others have
reported that pErk independently predicted for reduced sur-
vival [46,47]. In our patient cohort, there was a trend for pErk
to be associated with expression of HER4 (P = 0.07) and this
would indicate a preferable effect of pErk, but this was not evi-
dent in the Cox analysis. Moreover, the number of pErk and
pAkt targets is currently sought to be around 160 and 70 pro-
teins, respectively [48,49]. This fact is likely to, at least partly,
explain the discrepancies between the studies.
The comparison of the expression levels of the six proteins in
30 distant metastases and their corresponding primary tumors
disclosed a significant increase in expression of pHER1 and
pHER3 in the metastases. This observation fits well with the
poor prognosis of cases with primary tumors expressing the
phosphorylated receptors and, worthy of note, it indicates that
pHER1 and pHER3 may be important activators of HER2 in
metastatic tumor cell growth. We did not find other reports
investigating pHER1, pHER2 and pHER3 levels in this setting,
but eight other studies have, in agreement with our finding,
consistently found that the total HER2 expression, evaluated
by IHC, is unaltered between the primary and metastatic
lesions [50]. Analysis of activated HER1 and HER3 in distant
metastasis may therefore be helpful in the clinical setting.
Lastly, we observed a significant increase in the number of
cases with nuclear expression of pHER3 in the metastasis. No
data on nuclear HER3 expression exist in breast cancer, but a
recent report showed that nuclear HER3 was absent in non-
malignant prostate tissue, whereas it was highly expressed in
the cancerous prostate tissue and associated with increased
tumor grade [51]. Studies with more statistical power should
therefore investigate whether increased nuclear expression of
HER3 in metastatic lesions may be associated with an adverse
prognosis.
Conclusions
The present study shows that strong expression of activated
HER2 as well as activated HER1 and HER3 is associated with
poor prognosis in this series of hormone receptor-positive
breast cancer patients. We conclude that expression of HER2
phosphorylated at tyrosine 1221/1222 is likely to hold cur-
rently unassessed information on poor prognosis in hormone
receptor-positive breast cancer.
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